Brainstorm Cell Therapeutics Inc. (BCLI) News
Filter BCLI News Items
BCLI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BCLI News Highlights
- BCLI's 30 day story count now stands at 4.
- Over the past 19 days, the trend for BCLI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about BCLI are STEM, DRUG and PATH.
Latest BCLI News From Around the Web
Below are the latest news stories about BRAINSTORM CELL THERAPEUTICS INC that investors may wish to consider to help them evaluate BCLI as an investment opportunity.
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder TreatmentsBrainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes. |
BrainStorm Issues 2023 Letter to ShareholdersBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders. |
BCLI: FDA Meeting Provides Clear Path for Planned Phase 3b Trial of NurOwnBy David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Clear Path Forward for Phase 3b Trial of NurOwn On December 7, 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced the company attended a meeting with the U.S. Food and Drug Administration (FDA) regarding the planned Phase 3b trial for NurOwn in amyotrophic lateral sclerosis (ALS). The company is going |
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALSBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the completion of a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS). |
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALSBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the US Food & Drug Administration (US FDA) has granted the company a meeting to discuss the regulatory path forward for NurOwn® in amyotrophic lateral sclerosis (ALS). The meeting is scheduled to take place on December 6, 2023. Brainstorm will discuss plans for a Special Protocol Assessment (SPA) with the FDA to agree on the overall protocol d |
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research SymposiaBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE. The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data. The presentation, titled, "NurOwn for ALS: Biomarker e |
BCLI: Phase 3b Trial Details to be Discussed with FDA…By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Meeting with the FDA to Discuss Development Plan for NurOwn® in ALS On October 18, 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) has invited the company to request an expedited meeting to discuss the path forward for NurOwn® as a treatment for |
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call TranscriptBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Greetings, and welcome to the BrainStorm Cell Therapeutics Third Quarter 2023 Earnings Call. At this time, participants are in a listen-only mode. As a reminder, this call is being recorded. And I would now like to introduce your host for today’s […] |
Q3 2023 Brainstorm Cell Therapeutics Inc Earnings CallQ3 2023 Brainstorm Cell Therapeutics Inc Earnings Call |
BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate UpdateBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. |